Gerhard Schaefer graduated with a PhD in chemistry from Stuttgart University. During his more than 30 years in the generic pharmaceutical industry, he held a progression of senior management positions in development, quality assurance / control and business development at Azupharma, Knoll, Stada, Hexal and Sandoz.
Among his numerous responsibilities, he was appointed to head of development and business development at Hexal in 2001 and at the same time a member of the executive board of Hexal AG, one of Germany’s leading generic drug producers. Following the acquisition of Hexal AG by Novartis / Sandoz in 2005 and until February 2012, he served as managing director of Sandoz International as well as head of global product development and global business development at Sandoz, the world’s second largest generic pharmaceutical company, where he managed eleven development centers worldwide.
Dr. Bernhard Hampl
Over the past 20 years, Dr. Bernhard Hampl, who received his doctorate in the field of pharmaceutical chemistry, was a successful CEO of major American generic drug companies, notably EON LABS Inc. and later Sandoz US, which after their merger became America’s second-largest manufacturer of generics.
Dr. Hampl, who began his career at the German subsidiary of American Cyanamid / Lederle in Wolfratshausen near Munich, has been living in the U.S. state of Connecticut for the past 20 years and brings wide-ranging international experience to Formycon. He currently serves as an advisor to pharmaceutical and biotechnology companies as well as investment companies.
Prof. Dr. Johannes Buchner
After studying biology and receiving his PhD from the University of Regensburg in 1991, Professor Buchner investigated new concepts in cancer treatment during his postdoctoral work at the National Institutes of Health in Bethesda, USA. He then returned to the University of Regensburg to be promoted professor of biochemistry and since 1998 has served as professor of biotechnology at the Technical University of Munich, Germany. His research focuses on chaperone proteins and antibodies.
Professor Buchner is a member of the German Academy of Sciences (Leopoldina) as well as the Bavarian Academy of Sciences and Humanities. He has received numerous awards for his research, including the Hans Neurath Award from the Protein Society and the Schleiden Medal awarded by Leopoldina.
Thomas Siklosi is a renowned biotechnology executive and expert in the development and production of biologics and biosimilars. He gained his early professional experience in the field of biotechnology at Boehringer Mannheim. In 1984, he moved to the biotech pioneer Rentschler Arzneimittel and held various roles in the development and production of interferons, later being responsible at Rentschler Biotechnologie for biopharmaceutical substances.
In cooperation with a leading generic manufacturer, he was responsible as project manager for the technical development of the complex glycoprotein erythropoetin, which received approval as the first epoetin-alfa biosimilar in the EU in 2007. In September 2012, Siklosi was appointed to the board of management at Rentschler Biopharma SE. Siklosi is a member of the university council of Biberach University and holds numerous patents in the field of biotechnology.